A Phase 3 interventional study of Doxorubicin hydrochloride (liposomal) in Sarcoma, Kaposi and HIV Infections, sponsored by Sequus Pharmaceuticals. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Sequus Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Sarcoma, Kaposi with a site in United States — 13 open to participants now, 18 under way, none of them phase 3. Sarcoma, Kaposi · United States.
Among the 115 studies in Sarcoma, Kaposi with a site in United States, this one is one of 7 in phase 3, and was the 6th registered.
161 studies on the registry are indexed under Sarcoma, Kaposi; 24 are open to participants now.
Browse Sarcoma, Kaposi studies →13 of the 115 studies in Sarcoma, Kaposi with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Sarcoma, Kaposi studies recruiting now, 11 (52%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 47 · Phase 3 7
First in 1992; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 31 across the 82 interventional studies, 184 across the 16 observational. Of the 95 that completed or were terminated, 21 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 115 have an industry lead sponsor. The 10 most frequent:
Sequus Pharmaceuticals is the lead sponsor of 4 studies on the registry; none are open to participants now.
Sequus Pharmaceuticals has 4 studies filed under Sarcoma, Kaposi — fewer than ten, so there is no comparison to draw.
2 of the studies in Sarcoma, Kaposi with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04902443National Cancer Institute (NCI)Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | 2026-12-01 |
| NCT04577755National Cancer Institute (NCI)Pomalidomide Treatment in Patients With Kaposi Sarcoma | 2027-02-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies in Sarcoma, Kaposi with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treatment with another Kaposi's sarcoma therapy because of inadequate efficacy or unacceptable toxicity. To provide a defined protocol for Kaposi's sarcoma patients for whom DOX-SL therapy is indicated.
Patients receive DOX-SL every 3 weeks for a maximum of 20 cycles (including any cycles from a previous DOX-SL study). KS lesions are evaluated prior to administration of each treatment, at the end of the final treatment cycle, and at 4 weeks following the end of the final treatment. Patients who respond will be followed every 2 months for up to 1 year. Study treatment may be interrupted for up to 4 months because of complete response, development of opportunistic infections, or adverse drug effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concurrent Medication:
Allowed:
Patients must have:
NOTE:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded within the past 4 weeks:
Prior Treatment:
Excluded within the past 3 weeks:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Jan 1996. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin
Sequus Pharmaceuticals